Acurx Pharmaceuticals Files 8-K for Financial Updates
Ticker: ACXP · Form: 8-K · Filed: Nov 13, 2024 · CIK: 1736243
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: ACRX
TL;DR
ACRX filed an 8-K on Nov 13th for financial updates. Check for details.
AI Summary
Acurx Pharmaceuticals, Inc. filed an 8-K on November 13, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational details within the provided text, but indicates a formal reporting event.
Why It Matters
This 8-K filing signals that Acurx Pharmaceuticals is providing updated financial information and operational details to the SEC, which is crucial for investors to assess the company's current standing.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting financial condition and does not indicate any immediate adverse events or significant changes.
Key Players & Entities
- Acurx Pharmaceuticals, Inc. (company) — Registrant
- November 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40536 (identifier) — Commission File Number
- 259 Liberty Avenue, Staten Island, NY 10305 (address) — Principal executive offices
- ( 917 ) 533-1469 (phone_number) — Registrant's telephone number
FAQ
What specific financial results or conditions are being reported by Acurx Pharmaceuticals in this 8-K?
The provided text of the 8-K filing indicates it is for 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail the specific financial figures or conditions within this excerpt.
When was this 8-K filing submitted to the SEC?
The filing was submitted on November 13, 2024, as indicated by the 'Date of Report (Date of earliest event reported)'.
What is the principal business address of Acurx Pharmaceuticals, Inc.?
The principal executive offices are located at 259 Liberty Avenue, Staten Island, NY 10305.
What is the Commission File Number for Acurx Pharmaceuticals, Inc.?
The Commission File Number for Acurx Pharmaceuticals, Inc. is 001-40536.
What is the SIC code for Acurx Pharmaceuticals, Inc.?
The Standard Industrial Classification (SIC) code for Acurx Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-11-13 07:06:30
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ACXP The Nasdaq Stock Mar
Filing Documents
- tm2428175d1_8k.htm (8-K) — 25KB
- tm2428175d1_ex99-1.htm (EX-99.1) — 61KB
- 0001104659-24-117214.txt ( ) — 265KB
- acxp-20241113_lab.xml (EX-101.LAB) — 33KB
- acxp-20241113_pre.xml (EX-101.PRE) — 22KB
- acxp-20241113.xsd (EX-101.SCH) — 3KB
- tm2428175d1_8k_htm.xml (XML) — 4KB
02
Item 2.02 Results of Operations and Financial Condition. On November 13, 2024, Acurx Pharmaceuticals, Inc. (the "Company") issued a press release announcing its financial results for the third quarter ended September 30, 2024 and providing a business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release, dated November 13, 2024. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized. Acurx Pharmaceuticals, Inc. Date: November 13, 2024 By: /s/ David P. Luci Name: David P. Luci Title: President and Chief Executive Officer